List of Excipients in API halobetasol propionate and tazarotene
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing halobetasol propionate and tazarotene
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Bausch Health US LLC | DUOBRII | halobetasol propionate and tazarotene | 0187-0653 | CARBOMER COPOLYMER TYPE B | |
| Bausch Health US LLC | DUOBRII | halobetasol propionate and tazarotene | 0187-0653 | CARBOMER HOMOPOLYMER TYPE A | |
| Bausch Health US LLC | DUOBRII | halobetasol propionate and tazarotene | 0187-0653 | DIETHYL SEBACATE | |
| Bausch Health US LLC | DUOBRII | halobetasol propionate and tazarotene | 0187-0653 | EDETATE DISODIUM | |
| Bausch Health US LLC | DUOBRII | halobetasol propionate and tazarotene | 0187-0653 | LIGHT MINERAL OIL | |
| Bausch Health US LLC | DUOBRII | halobetasol propionate and tazarotene | 0187-0653 | METHYLPARABEN | |
| Bausch Health US LLC | DUOBRII | halobetasol propionate and tazarotene | 0187-0653 | PROPYLPARABEN | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for halobetasol propionate and tazarotene
Excipient focus: CARBOMER COPOLYMER TYPE B
halobetasol propionate and tazarotene drug variants containing CARBOMER COPOLYMER TYPE B
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | halobetasol propionate and tazarotene | 0187-0653 |
| >Company | >Ingredient | >NDC |
halobetasol propionate and tazarotene drug variants not containing CARBOMER COPOLYMER TYPE B
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CARBOMER HOMOPOLYMER TYPE A
halobetasol propionate and tazarotene drug variants containing CARBOMER HOMOPOLYMER TYPE A
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | halobetasol propionate and tazarotene | 0187-0653 |
| >Company | >Ingredient | >NDC |
halobetasol propionate and tazarotene drug variants not containing CARBOMER HOMOPOLYMER TYPE A
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: DIETHYL SEBACATE
halobetasol propionate and tazarotene drug variants containing DIETHYL SEBACATE
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | halobetasol propionate and tazarotene | 0187-0653 |
| >Company | >Ingredient | >NDC |
halobetasol propionate and tazarotene drug variants not containing DIETHYL SEBACATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: EDETATE DISODIUM
halobetasol propionate and tazarotene drug variants containing EDETATE DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | halobetasol propionate and tazarotene | 0187-0653 |
| >Company | >Ingredient | >NDC |
halobetasol propionate and tazarotene drug variants not containing EDETATE DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LIGHT MINERAL OIL
halobetasol propionate and tazarotene drug variants containing LIGHT MINERAL OIL
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | halobetasol propionate and tazarotene | 0187-0653 |
| >Company | >Ingredient | >NDC |
halobetasol propionate and tazarotene drug variants not containing LIGHT MINERAL OIL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: METHYLPARABEN
halobetasol propionate and tazarotene drug variants containing METHYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | halobetasol propionate and tazarotene | 0187-0653 |
| >Company | >Ingredient | >NDC |
halobetasol propionate and tazarotene drug variants not containing METHYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLPARABEN
halobetasol propionate and tazarotene drug variants containing PROPYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | halobetasol propionate and tazarotene | 0187-0653 |
| >Company | >Ingredient | >NDC |
halobetasol propionate and tazarotene drug variants not containing PROPYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM HYDROXIDE
halobetasol propionate and tazarotene drug variants containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | halobetasol propionate and tazarotene | 0187-0653 |
| >Company | >Ingredient | >NDC |
halobetasol propionate and tazarotene drug variants not containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SORBITAN MONOOLEATE
halobetasol propionate and tazarotene drug variants containing SORBITAN MONOOLEATE
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | halobetasol propionate and tazarotene | 0187-0653 |
| >Company | >Ingredient | >NDC |
halobetasol propionate and tazarotene drug variants not containing SORBITAN MONOOLEATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SORBITOL
halobetasol propionate and tazarotene drug variants containing SORBITOL
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | halobetasol propionate and tazarotene | 0187-0653 |
| >Company | >Ingredient | >NDC |
halobetasol propionate and tazarotene drug variants not containing SORBITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
halobetasol propionate and tazarotene drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| Bausch Health US LLC | halobetasol propionate and tazarotene | 0187-0653 |
| >Company | >Ingredient | >NDC |
halobetasol propionate and tazarotene drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch